| Chairman of the Board and Chief Executive Officer
Albert Cha, M.D., Ph.D.
| Managing Partner, Vivo Ventures
John Doux, M.D.
| Analyst, Palo Alto Investors
| Principal, Osage Ventures
william Hamilton, Ph.D.
| Ralph Landau Professor of Management and Technology
Chairman of the Board and Chief Executive Officer
Joining Ceptaris in May
2011, Mr. Tullman brings more than 21 years of
biopharmaceutical global commercialization and drug
development experience. Mr. Tullman formerly served
as the Executive Chairman of Vicept Therapeutics,
which was acquired by Allergan Therapeutics in July
and has co-founded and led numerous companies: Ception Therapeutics, a biologics company (acquired
by Cephalon); Trigenesis Therapeutics, a dermatology
company (acquired by Dr. Reddy’s Laboratories); and
Cutix Pharmaceuticals, a privately held dermatology
company. He also served on the Board of Directors
for Euromed, a wound care company. Mr. Tullman
started his career at GlaxoSmithKline and held
positions of increasing responsibility in finance,
sales, marketing, and research and development. Mr.
Tullman earned a B.S. from Rutgers University in New
Albert Cha, M.D., Ph.D.,
Managing Partner, Vivo Ventures
As managing partner of
Vivo Ventures, Dr. Albert Cha invests in private and
public biopharmaceutical and medical device
companies. He currently serves on the board of
several private biopharmaceutical and medical device
companies and has also served as co-founder of
several portfolio companies. Prior to joining Vivo,
Albert worked at Oracle Corporation in
pharmaceutical consulting and at the Palo Alto VA
Hospital as a biomedical engineer. He completed the
Medical Scientist Training Program at UCLA School of
Medicine, where he received his M.D. and Ph.D. in
Neuroscience. During his studies, he was elected to
Alpha Omega Alpha and won the prestigious
Outstanding Graduate Student Award. He earned his
B.S. and M.S. in Electrical Engineering from
John Doux, M.D.,
Analyst, Palo Alto Investors
John Doux has been an analyst at Palo Alto Investors since 2004. He obtained a B.S. with distinction and an M.D. from Stanford University, where he was a Howard Hughes Medical Institute Fellow. He also completed an M.B.A. at the Wharton School of Business where he was a Palmer Scholar. He is board certified in dermatology and maintains an active clinical practice.
Principal, Osage Ventures
David began his career at
Teradyne, Inc., a Boston-based manufacturer of
semiconductor test equipment, where he was a
mechanical engineer before becoming a project
manager. He then attended The Wharton School, where
he graduated with an M.B.A. in Entrepreneurship.
While at Wharton, Mr. Drahms spent the summer as an
internal strategist with Rohm and Haas, traveled to
Peru to advise a consumer textiles company on a U.S.
market entry strategy, and consulted with Teach for
America on how to optimize their recruitment
process. Mr. Drahms serves on the Board of Directors
for Red Lasso and is a Board Observer for Melior
Discovery and HardMetrics.
william Hamilton, Ph.D.,
Ralph Landau Professor of Management and Technology,
University of Pennsylvania
Dr. Hamilton has served on
the University of Pennsylvania faculty since 1967.
He is the Ralph Landau Professor of Management and
Technology and Director of the Jerome Fisher Program
in Management and Technology at The Wharton School
and the School of Engineering and Applied Science.
He also serves as a Director of Arno Therapeutics,
Inc., a life sciences company. He previously served
as a Director of Avid Radiopharmaceuticals, Inc.
prior to its acquisition by Eli Lilly and Centocor,
Inc. prior to its acquisition by Johnson & Johnson.
Dr. Hamilton earned his Ph.D. in Applied Economics
from the London School of Economics, and received
his M.B.A. and a M.S. and B.S. in Chemical
Engineering from the University of Pennsylvania.